- Most patients that experienced clinical response, clinical remission, or endoscopic improvement with etrasimod 2 mg in the Phase 2 OASIS trial observed sustained or improved effects up to week 46 of treatment
- Etrasimod demonstrated a favorable safety profile, consistent with the double-blind portion of OASIS
PR Newswire
SAN DIEGO, Calif., Oct. 22, 2019